摘要:
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要:
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要:
Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
摘要翻译:本文提供了通过施用胰岛淀粉样多肽激动剂化合物治疗哺乳动物雌激素缺乏症的方法。 本文还提供了在雌激素缺乏的哺乳动物中治疗肥胖和超重的方法; 在雌激素缺乏的哺乳动物中减少或维持体重和/或体内脂肪的方法; 以及通过施用有效量的胰淀素激动剂化合物来增加哺乳动物中Bdnf水平的方法。 雌激素缺乏可能是由更年期,绝经前期,绝经后,卵巢功能障碍,过度切除术,子宫切除术等引起的。 胰淀素激动剂化合物可以是本领域已知的或本文所述的任何一种,例如普兰林肽,达维兰苷或SEQ ID NO:142。
摘要:
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要:
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.